{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:37:49Z","timestamp":1778701069107,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.dld.2024.04.032","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:31:28Z","timestamp":1715959888000},"page":"1281-1287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trifluridine\/tipiracil + oxaliplatin \u00b1 nivolumab vs FOLFOX \u00b1 nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial"],"prefix":"10.1016","volume":"56","author":[{"given":"Damien","family":"Botsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-6867","authenticated-orcid":false,"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanifa","family":"Ammarguellat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Jestin-Le-Tallec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Olesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Toullec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-6927","authenticated-orcid":false,"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meher","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"Olivier","family":"Bouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-6957","authenticated-orcid":false,"given":"Cl\u00e9lia","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2950-1134","authenticated-orcid":false,"given":"Herv\u00e9","family":"Devaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-0423","authenticated-orcid":false,"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Huguenin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Guillaume","family":"Poureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Oularue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"De Sousa Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-9910","authenticated-orcid":false,"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"De La Fouchardiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dld.2024.04.032_bib0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-017-0510-0","article-title":"The role of systemic therapy in resectable gastric and gastro-oesophageal junction cancer","volume":"18","author":"Cartwright","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"10.1016\/j.dld.2024.04.032_bib0002","doi-asserted-by":"crossref","first-page":"1286\u2011312","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.dld.2024.04.032_bib0003","doi-asserted-by":"crossref","first-page":"1435\u201142","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10294","key":"10.1016\/j.dld.2024.04.032_bib0005","doi-asserted-by":"crossref","first-page":"27\u201140","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dld.2024.04.032_bib0006","doi-asserted-by":"crossref","first-page":"1181\u201195","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.dld.2024.04.032_bib0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.dld.2018.01.119","article-title":"Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)","volume":"50","author":"Zaanan","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.04.032_bib0007","doi-asserted-by":"crossref","first-page":"S1318","DOI":"10.1016\/j.annonc.2023.10.078","volume":"34","author":"Zaanan","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2024.04.032_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102289","article-title":"Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature","volume":"100","author":"de la Fouchardiere","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.dld.2024.04.032_bib0009","doi-asserted-by":"crossref","first-page":"869\u201177","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.dld.2024.04.032_bib0010","doi-asserted-by":"crossref","first-page":"1909\u201119","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.032_bib0011","doi-asserted-by":"crossref","first-page":"63\u201172","DOI":"10.1016\/j.ejca.2017.10.009","article-title":"The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer","volume":"90","author":"Van Cutsem","year":"2018","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.dld.2024.04.032_bib0012","doi-asserted-by":"crossref","first-page":"1657\u201167","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.dld.2024.04.032_bib0013","doi-asserted-by":"crossref","first-page":"1437\u201148","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.dld.2024.04.032_bib0016","doi-asserted-by":"crossref","first-page":"1005\u201120","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.dld.2024.04.032_bib0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12032-022-01698-9","volume":"39","author":"Dayyani","year":"2022","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.dld.2024.04.032_bib0018","doi-asserted-by":"crossref","first-page":"209\u201117","DOI":"10.1016\/S2468-1253(20)30396-4","article-title":"Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial","volume":"6","author":"Kawazoe","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.032_bib0019","doi-asserted-by":"crossref","first-page":"12\u20119","DOI":"10.1016\/j.ejca.2019.01.101","article-title":"Phase I dose-escalation of trifluridine\/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer","volume":"112","author":"Argil\u00e9s","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.dld.2024.04.032_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100270","article-title":"Trifluridine\/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study","volume":"6","author":"Bordonaro","year":"2021","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.dld.2024.04.032_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007315","article-title":"Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer","volume":"11","author":"Decazes","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.dld.2024.04.032_bib0022","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/diagnostics13020205","article-title":"Body composition to define prognosis of cancers treated by anti-angiogenic drugs","volume":"13","author":"Decazes","year":"2023","journal-title":"Diagnostics"},{"issue":"28","key":"10.1016\/j.dld.2024.04.032_bib0023","doi-asserted-by":"crossref","first-page":"7199\u2011206","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase ii screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.dld.2024.04.032_bib0024","doi-asserted-by":"crossref","first-page":"768\u201179","DOI":"10.1016\/j.dld.2018.04.025","article-title":"Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)","volume":"50","author":"Zaanan","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.dld.2024.04.032_bib0025","doi-asserted-by":"crossref","first-page":"2133\u201141","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"10389","key":"10.1016\/j.dld.2024.04.032_bib0026","doi-asserted-by":"crossref","first-page":"1655\u201168","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dld.2024.04.032_bib0027","doi-asserted-by":"crossref","first-page":"1430\u201140","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.dld.2024.04.032_bib0030","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T11:28:54Z","timestamp":1722079734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1590865824007333"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.032","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trifluridine\/tipiracil + oxaliplatin \u00b1 nivolumab vs FOLFOX \u00b1 nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}